PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1544591
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1544591
Alzheimer's Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
Alzheimer's Therapeutics Market size is set to record a 9.8% CAGR from 2024 to 2032 due to increased government funding and support.
Governments worldwide are channeling significant funds into R and D, aiming to discover effective treatments and potential cures for Alzheimer's disease. This financial backing empowers scientists to delve into innovative therapeutic avenues, encompassing drug development, gene therapy, and cutting-edge diagnostic tools. Furthermore, the strengthened partnerships between public institutions and private entities are propelling advancements in treatment options. For instance, in January 2023, the U.S. FDA granted accelerated approval to Leqembi (lecanemab-irmb). This endorsement signifies a pivotal advancement in addressing the core pathology of Alzheimer's disease.
The alzheimer's therapeutics industry is segmented into drug class, route of administration, distribution channel, and region.
The market share from the combination drug class segment is poised to witness a robust CAGR from 2024 to 2032 attributed to the growing emphasis on enhancing treatment efficacy by simultaneously targeting multiple pathways associated with the disease. These combination drugs leverage diverse mechanisms to tackle various facets of Alzheimer's, including reducing amyloid plaques and boosting cognitive functions. Ongoing research is delving into the potential of these multi-targeted agents, suggesting they might offer a holistic approach for outpacing traditional single-drug therapies.
By distribution channel, the online pharmacy segment of the alzheimer's therapeutics market is set to experience a notable CAGR from 2024 to 2032. This is fueled by the increasing consumer demand for convenient medication access. Online platforms are not only providing a spectrum of Alzheimer's treatments, including cutting-edge therapies but are also ensuring enhanced privacy and ease in ordering and delivery to significantly aid patients in managing their conditions.
Asia Pacific alzheimer's therapeutics industry will register a substantial CAGR through 2032. This growth is driven by an aging populace and the surging prevalence of Alzheimer's in the region. As the elderly population swells, the demand for effective treatments will also rise. In response, researchers and healthcare professionals are rolling out tailored therapeutics to meet the unique needs of this expanding demographic. The intensified focus on combating Alzheimer's is not only refining treatment options but also bolstering patient outcomes to ensure better disease management amidst its rising prevalence.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of Alzheimer's disease
- 3.2.1.2 Technological advancements in diagnostics
- 3.2.1.3 Growing awareness and diagnosis rates
- 3.2.1.4 Favorable reimbursement policies
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of drug development
- 3.2.2.2 High failure rate in clinical trials
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 By stage of disease
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
- 3.9 Future market trends
- 3.10 GAP analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Vendor matrix analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Cholinesterase inhibitors
- 5.3 NMDA receptor antagonist
- 5.4 Combination drugs
- 5.5 Glutamate inhibitors
- 5.6 MAO inhibitors
- 5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Oral
- 6.3 Injectable
- 6.4 Transdermal patch
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacy
- 7.3 Retail pharmacy
- 7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AbbVie Inc.
- 9.2 Amgen Inc.
- 9.3 AstraZeneca
- 9.4 Biogen
- 9.5 Cipla Inc.
- 9.6 Daiichi Sankyo Company, Limited
- 9.7 Eisai Co., Ltd.
- 9.8 Eli Lilly and Company
- 9.9 H. Lundbeck A/S
- 9.10 Merck and Co., Inc.
- 9.11 Novartis AG
- 9.12 Otsuka Pharmaceutical Co., Ltd.
- 9.13 Pfizer, Inc.
- 9.14 Sanofi
- 9.15 Sun Pharmaceutical Industries Ltd.
